Literature DB >> 15319291

Patients with severe sepsis vary markedly in their ability to generate activated protein C.

Patricia C Y Liaw1, Charles T Esmon, Kamyar Kahnamoui, Shelley Schmidt, Sarah Kahnamoui, Gary Ferrell, Suzanne Beaudin, Jim A Julian, Jeffrey I Weitz, Mark Crowther, Mark Loeb, Deborah Cook.   

Abstract

Activated protein C (APC) supplementation significantly reduces mortality in patients with severe sepsis, presumably by down-regulating coagulation, inflammation, and apoptosis. In vivo, endogenous APC is generated from protein C (PC) "on demand" in response to elevated thrombin levels. Thrombomodulin and endothelial cell protein C receptor are endothelial receptors required to generate APC endogenously. Since these receptors may be down-regulated in sepsis, we measured plasma markers of APC generation in 32 patients with severe sepsis to determine whether APC generation is impaired and whether markers of APC generation correlate with 28-day mortality. Relative to normals, all patients had elevated F1 + 2 and thrombin-antithrombin complex (TAT) levels (markers of thrombin generation and inhibition, respectively), and 28 of 32 patients had reduced PC levels. In 20 patients, APC levels paralleled elevated F1 + 2 levels, whereas 12 patients had low APC levels despite elevated F1 + 2 levels, suggesting that APC generation is impaired in the latter. No significant differences exist between survivors and nonsurvivors with respect to baseline PC levels, F1 + 2 levels, and APACHE II (acute physiology and chronic health evaluation) scores. Baseline APC levels were higher in survivors (P = .024), and baseline F1 + 2/APC ratios were lower in survivors (P = .047). Larger studies are warranted to establish whether APC generation profiles aid in managing sepsis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319291     DOI: 10.1182/blood-2004-03-1203

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. [corrected]

Authors:  Marco Cicardi
Journal:  Intern Emerg Med       Date:  2010-03-27       Impact factor: 3.397

Review 2.  Sepsis: a clinical update.

Authors:  Corey E Ventetuolo; Mitchell M Levy
Journal:  Clin J Am Soc Nephrol       Date:  2007-11-07       Impact factor: 8.237

3.  Protein C -1641A/-1654C haplotype is associated with organ dysfunction and the fatal outcome of severe sepsis in Chinese Han population.

Authors:  Qi Xing Chen; Shui Jing Wu; Hai Hong Wang; Chen Lv; Bao Li Cheng; Guo Hao Xie; Xiang Ming Fang
Journal:  Hum Genet       Date:  2008-02-05       Impact factor: 4.132

4.  Age-dependent vulnerability to endotoxemia is associated with reduction of anticoagulant factors activated protein C and thrombomodulin.

Authors:  Marlene E Starr; Junji Ueda; Hitoshi Takahashi; Hartmut Weiler; Charles T Esmon; B Mark Evers; Hiroshi Saito
Journal:  Blood       Date:  2010-03-26       Impact factor: 22.113

Review 5.  The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications.

Authors:  Silvio Danese; Stefania Vetrano; Li Zhang; Victoria A Poplis; Francis J Castellino
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

Review 6.  Clinical review: a review and analysis of heart rate variability and the diagnosis and prognosis of infection.

Authors:  Saif Ahmad; Anjali Tejuja; Kimberley D Newman; Ryan Zarychanski; Andrew Je Seely
Journal:  Crit Care       Date:  2009-11-24       Impact factor: 9.097

7.  Plasma protein C levels in immunocompromised septic patients are significantly lower than immunocompetent septic patients: a prospective cohort study.

Authors:  Rakshit Panwar; Bala Venkatesh; Peter Kruger; Robert Bird; Devinder Gill; Leo Nunnink; Goce Dimeski
Journal:  J Hematol Oncol       Date:  2009-10-19       Impact factor: 17.388

8.  Sepsis-associated disseminated intravascular coagulation and thromboembolic disease.

Authors:  Nicola Semeraro; Concetta T Ammollo; Fabrizio Semeraro; Mario Colucci
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-08-13       Impact factor: 2.576

Review 9.  Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.

Authors:  Hartmut Weiler; Wolfram Ruf
Journal:  Curr Opin Hematol       Date:  2008-09       Impact factor: 3.284

10.  Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.

Authors:  Laith Altaweel; Daniel Sweeney; Xizhong Cui; Amisha Barochia; Charles Natanson; Peter Q Eichacker
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.